OregonGreen 488

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并吡喃
• 英文名称: OregonGreen 488
• 英文别名: Oregon green 488 carboxylate；4-(2,7-difluoro-3-hydroxy-6-oxoxanthen-9-yl)benzene-1,3-dicarboxylic acid
• 化学式: C₂₁H₁₀F₂O₇
• 分子量: 412.303
• InChiKey: BRJCLSQFZSHLRL-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.4
• 重原子数：
  30
• 可旋转键数：
  3
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  121
• 氢给体数：
  3
• 氢受体数：
  9

反应信息

• 作为反应物：
  描述：

  、 OregonGreen 488 在 N-羟基-7-氮杂苯并三氮唑 、 N,N-二异丙基乙胺 、 N-[(dimethylamino)-3-oxo-1H-1,2,3-triazolo[4,5-b]pyridin-1-yl-methylene]-N-methylmethanaminium hexafluorophosphate 作用下， 以 二甲基亚砜 为溶剂， 反应 10.0h， 以25%的产率得到2-(2,7-difluoro-6-hydroxy-3-oxo-3H-xanthen-9-yl)-5-((2-(2-(2-((2,4-dinitrophenyl)amino)ethoxy)ethoxy)ethyl)carbamoyl)benzoic acid
  参考文献：
  名称：

  Live-cell imaging of multiple endogenous mRNAs permits the direct observation of RNA granule dynamics

  摘要：

  一种多色RNA成像技术允许直接观察活细胞中的应激颗粒形成。

  DOI：

  10.1039/c8cc03805h
• 作为产物：
  描述：

  3',6'-diacetoxy-2',7'-difluoro-3-oxo-3H-spiro[isobenzofuran-1,9'-xanthene]-5-carboxylic acid 在 ammonium hydroxide 作用下， 以 甲醇 、 水 为溶剂， 反应 2.0h， 以83%的产率得到OregonGreen 488
  参考文献：
  名称：

  Synthesis of Fluorinated Fluoresceins

  摘要：

  Several novel fluorinated fluoresceins (Oregon Green dyes) were prepared by the reaction of fluororesorcinols with phthalic anhydride and its derivatives. A novel regiospecific synthesis of fluororesorcinols was key to the successful synthesis of these new fluorophores. (Polyfluoro)-nitrobenzenes were reacted with 2 equiv of sodium methoxide followed by reduction, hydrodediazoniation, and demethylation, giving the first straightforward synthesis of 2-fluororesorcinol, 4-fluororesorcinol, 2,4-difluororesorcinol, and 2,4,5-trifluororesorcinol. These fluorinated fluoresceins have higher photostability and ionize at a lower pH (pK(a) = 3.3-6.1) than fluorescein (pK(a) = 6.5). Some of the fluorinated fluoresceins have very high quantum yields (0.85-0.97), which, in combination with their lower pK(a)s and high photostability, makes them superior fluorescent dyes for use as reporter molecules in biological systems.

  DOI：

  10.1021/jo9706178

文献信息

• Labeling reagents and methods of their use
  申请人：Gee Kyle

  公开号：US08586743B2

  公开（公告）日：2013-11-19

  The present disclosure is directed to a reactive ester agent capable of conjugating a reporter molecule to a carrier molecule or solid support. The reactive ester agent has the general formula: wherein the variables are described throughout the application.

  本发明涉及一种反应性酯化剂，其能够将报告分子共轭到载体分子或固体支持物上。该反应性酯化剂具有以下通式： 其中，各变量在申请文件中均有描述。
• Affinity-Guided Oxime Chemistry for Selective Protein Acylation in Live Tissue Systems
  作者：Tomonori Tamura、Zhining Song、Kazuma Amaike、Shin Lee、Sifei Yin、Shigeki Kiyonaka、Itaru Hamachi

  DOI：10.1021/jacs.7b07339

  日期：2017.10.11

  modification method using a catalytic acyl transfer reaction. However, because of the high electrophilicity of the thioester acyl donor molecule, AGD chemistry suffers from nonspecific reactions to proteins other than the target protein in crude biological environments, such as cell lysates, live cells, and tissue samples. To overcome this shortcoming, we here report a new acyl donor/organocatalyst system that

  催化剂介导的蛋白质修饰是一种强大的天然蛋白质成像和工程方法。我们以前开发了亲和引导的 4-二甲氨基吡啶 (AGD) 化学作为使用催化酰基转移反应的有效蛋白质修饰方法。然而，由于硫酯酰基供体分子的高亲电性，AGD 化学会在原始生物环境（如细胞裂解物、活细胞和组织样本）中与目标蛋白以外的蛋白质发生非特异性反应。为了克服这一缺点，我们在此报告了一种新的酰基供体/有机催化剂系统，可以进行更具体和有效的蛋白质修饰。在该方法中，高度亲核的吡啶鎓肟 (PyOx) 催化剂与目标蛋白的特异性配体结合。配体连接的 PyOx 选择性地与目标蛋白质结合，并促进蛋白质表面上温和的亲电 N-酰基-N-烷基磺酰胺酰基供体的酰基转移反应。我们证明了称为 AGOX（亲和性引导肟）化学的新催化系统可以修饰试管和细胞裂解物中的靶蛋白，比 AGD 化学更具选择性和效率。活细胞中内源性细胞膜蛋白、碳酸酐酶 XII 和叶酸受体的低背
• LABELING REAGENTS AND METHODS OF THEIR USE
  申请人：Antoulinakis Evan

  公开号：US20090004753A1

  公开（公告）日：2009-01-01

  The present disclosure is directed to a reactive ester agent capable of conjugating a reporter molecule to a carrier molecule or solid support. The reactive ester agent has the general formula: wherein the variables are described throughout the application.

  本公开涉及一种反应性酯试剂，能够将报告分子与载体分子或固体支持物共轭。该反应性酯试剂具有以下通式：其中变量在本申请中进行了描述。
• COMPOSITIONS AND METHODS FOR TRANSPORT OF MOLECULES WITH ENHANCED RELEASE PROPERTIES ACROSS BIOLOGICAL BARRIERS
  申请人：Wender Paul A

  公开号：US20100255499A1

  公开（公告）日：2010-10-07

  Conjugates of a cargo molecule with a transporter molecule are disclosed, where the cargo molecule and the transporter molecule are linked covalently by a releasable linker. The cargo of the conjugate can be a biologically active agent or a reporter molecule. The transporter modulates the transport of the cargo across a biological barrier (e.g., a cell membrane) compared to the transport of the unconjugated cargo. Releasable linkers suitable for rapid and facile conjugation to various types of cargo and transporters are also disclosed, along with methods for using the linkers in the synthesis of conjugates.

  本发明公开了一种货物分子与运输蛋白分子的共轭体，其中货物分子和运输蛋白分子通过可释放的连接剂共价连接。共轭体的货物可以是生物活性剂或报告分子。与未共轭货物的运输相比，运输蛋白调节货物通过生物屏障（例如细胞膜）的运输。还公开了适用于快速和容易地与各种类型的货物和运输蛋白共轭的可释放连接剂，以及使用连接剂合成共轭体的方法。
• Pharmaceutical Compounds Targeted by MIF Affinity-Tethered Moieties
  申请人：RJS Biologics LLC

  公开号：US20150352217A1

  公开（公告）日：2015-12-10

  There is disclosed a compound, a pharmaceutical composition and a method of treatment using a pharmaceutical composition comprising a tethering moiety that is capable of binding to a macrophage migration inhibitory factor (MIF) polypeptide, optionally linked to a linker moiety and further covalently bound to a drug moiety or imaging agent. More specifically, there is disclosed a genus of affinity-tethering moieties covalently bound to a drug moiety or imaging agent either directly or optionally via a linker moiety to covalently link the tethering moiety to a drug moiety. Without being bound by theory, the disclosed pharmaceutical compounds are targeted to cancer cells or immune cells via an affinity-tethering moiety that hitch-hikes to or into its target cell while bound to endogenous MIF.

  本发明涉及一种化合物、一种药物组合物和使用药物组合物的治疗方法，其中药物组合物包括一种可结合到巨噬细胞迁移抑制因子（MIF）多肽的系留基，可选地与连接基团连接，并进一步共价结合到药物基团或成像剂上。更具体地，本发明涉及一类亲和系留基，它们与药物基团或成像剂直接或可选地通过连接基团共价结合，以共价连接系留基和药物基团。本发明所披露的药物化合物通过亲和系留基定向靶向癌细胞或免疫细胞，系留基通过与内源性MIF结合，搭便车到达或进入其靶细胞。